GOSSAMER BIO, INC. Operating Expenses
GOSSAMER BIO, INC. (GOSS) reported Operating Expenses of $35.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- GOSSAMER BIO, INC. operating expenses for the quarter ending 2026-06-30 was $35.31M, a 29.73% decline year-over-year.
- GOSSAMER BIO, INC. operating expenses for the quarter ending 2026-03-31 was $61.82M, a 32.38% increase year-over-year.
- GOSSAMER BIO, INC. operating expenses for the quarter ending 2025-12-31 was $59.84M, a 31.49% increase year-over-year.
- GOSSAMER BIO, INC. operating expenses for the quarter ending 2025-09-30 was $62.41M, a 43.80% increase year-over-year.
- GOSSAMER BIO, INC. operating expenses for fiscal 2025 was $219.20M, a 25.53% increase from fiscal 2024.
- GOSSAMER BIO, INC. operating expenses for fiscal 2024 was $174.62M, a 4.97% decline from fiscal 2023.
- GOSSAMER BIO, INC. operating expenses for fiscal 2023 was $183.76M, a 15.94% decline from fiscal 2022.
- GOSSAMER BIO, INC. operating expenses for fiscal 2022 was $218.59M, a 1.14% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.31M 10-Q · filed 2026-08-13 | $97.13M 10-Q · filed 2026-08-13 | $156.97M derived: sum of 3 quarters · filed 2026-08-13 | $219.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $61.82M 10-Q · filed 2026-05-15 | $121.66M derived: sum of 2 quarters · filed 2026-05-15 | $184.07M derived: sum of 3 quarters · filed 2026-05-15 | $234.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $59.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $122.25M derived: sum of 2 quarters · filed 2026-03-17 | $172.50M derived: sum of 3 quarters · filed 2026-08-13 | $219.20M 10-K · filed 2026-03-17 |
| 2025-09-30 | $62.41M 10-Q · filed 2025-11-05 | $112.66M derived: sum of 2 quarters · filed 2026-08-13 | $159.36M 10-Q · filed 2025-11-05 | $204.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $50.25M 10-Q · filed 2026-08-13 | $96.95M 10-Q · filed 2026-08-13 | $142.46M derived: sum of 3 quarters · filed 2026-08-13 | $185.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $46.70M 10-Q · filed 2026-05-15 | $92.21M derived: sum of 2 quarters · filed 2026-05-15 | $135.60M derived: sum of 3 quarters · filed 2026-05-15 | $179.36M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $45.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $88.91M derived: sum of 2 quarters · filed 2026-03-17 | $132.66M derived: sum of 3 quarters · filed 2026-03-17 | $174.62M 10-K · filed 2026-03-17 |
| 2024-09-30 | $43.40M 10-Q · filed 2025-11-05 | $87.15M derived: sum of 2 quarters · filed 2025-11-05 | $129.11M 10-Q · filed 2025-11-05 | $178.14M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $43.76M 10-Q · filed 2025-08-05 | $85.71M 10-Q · filed 2025-08-05 | $134.74M derived: sum of 3 quarters · filed 2026-03-17 | $175.23M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $41.96M 10-Q · filed 2025-05-15 | $90.99M derived: sum of 2 quarters · filed 2026-03-17 | $131.48M derived: sum of 3 quarters · filed 2026-03-17 | $177.78M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $49.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $89.52M derived: sum of 2 quarters · filed 2026-03-17 | $135.82M derived: sum of 3 quarters · filed 2026-03-17 | $183.76M 10-K · filed 2026-03-17 |
| 2023-09-30 | $40.49M 10-Q · filed 2024-11-07 | $86.79M derived: sum of 2 quarters · filed 2024-11-07 | $134.73M 10-Q · filed 2024-11-07 | $189.09M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $46.30M 10-Q · filed 2024-08-12 | $94.24M 10-Q · filed 2024-08-12 | $148.60M derived: sum of 3 quarters · filed 2025-03-13 | $204.62M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $47.94M 10-Q · filed 2024-05-07 | $102.30M derived: sum of 2 quarters · filed 2025-03-13 | $158.32M derived: sum of 3 quarters · filed 2025-03-13 | $212.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $54.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $110.38M derived: sum of 2 quarters · filed 2025-03-13 | $164.25M derived: sum of 3 quarters · filed 2025-03-13 | $218.59M 10-K · filed 2025-03-13 |
| 2022-09-30 | $56.02M 10-Q · filed 2023-11-09 | $109.89M derived: sum of 2 quarters · filed 2023-11-09 | $164.24M 10-Q · filed 2023-11-09 | $215.90M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $53.87M 10-Q · filed 2023-08-08 | $108.22M 10-Q · filed 2023-08-08 | $159.88M derived: sum of 3 quarters · filed 2024-03-05 | $215.54M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $54.34M 10-Q · filed 2023-05-09 | $106.00M derived: sum of 2 quarters · filed 2024-03-05 | $161.67M derived: sum of 3 quarters · filed 2024-03-05 | $217.26M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $51.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $107.33M derived: sum of 2 quarters · filed 2024-03-05 | $162.92M derived: sum of 3 quarters · filed 2024-03-05 | $216.12M 10-K · filed 2024-03-05 |
| 2021-09-30 | $55.66M 10-Q · filed 2022-11-03 | $111.26M derived: sum of 2 quarters · filed 2022-11-03 | $164.46M 10-Q · filed 2022-11-03 | $224.55M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | $55.60M 10-Q · filed 2022-08-09 | $108.80M 10-Q · filed 2022-08-09 | $168.89M derived: sum of 3 quarters · filed 2023-03-17 | $222.46M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | $53.20M 10-Q · filed 2022-05-10 | $113.29M derived: sum of 2 quarters · filed 2023-03-17 | $166.86M derived: sum of 3 quarters · filed 2023-03-17 | $232.20M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $60.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $113.66M derived: sum of 2 quarters · filed 2023-03-17 | $179.00M derived: sum of 3 quarters · filed 2023-03-17 | $233.96M 10-K · filed 2023-03-17 |
| 2020-09-30 | $53.57M 10-Q · filed 2021-11-08 | $118.91M derived: sum of 2 quarters · filed 2021-11-08 | $173.88M 10-Q · filed 2021-11-08 | $229.66M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $65.34M 10-Q · filed 2021-08-09 | $120.31M 10-Q · filed 2021-08-09 | $176.09M derived: sum of 3 quarters · filed 2022-03-03 | $226.08M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $54.97M 10-Q · filed 2021-05-06 | $110.75M derived: sum of 2 quarters · filed 2022-03-03 | $160.74M derived: sum of 3 quarters · filed 2022-03-03 | $207.09M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $55.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $105.77M derived: sum of 2 quarters · filed 2022-03-03 | $152.12M derived: sum of 3 quarters · filed 2022-03-03 | $186.14M 10-K · filed 2022-03-03 |
| 2019-09-30 | $49.99M 10-Q · filed 2020-11-10 | $96.33M derived: sum of 2 quarters · filed 2020-11-10 | $130.35M 10-Q · filed 2020-11-10 | $170.16M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $46.35M 10-Q · filed 2020-08-11 | $80.37M 10-Q · filed 2020-08-11 | $120.17M derived: sum of 3 quarters · filed 2021-02-26 | $170.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $34.02M 10-Q · filed 2020-05-12 | $73.82M derived: sum of 2 quarters · filed 2021-02-26 | $123.85M derived: sum of 3 quarters · filed 2021-02-26 | $156.88M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $39.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $89.83M derived: sum of 2 quarters · filed 2021-02-26 | $122.87M derived: sum of 3 quarters · filed 2021-02-26 | $148.99M 10-K · filed 2021-02-26 |
| 2018-09-30 | $50.02M 10-Q · filed 2019-11-12 | $83.06M derived: sum of 2 quarters · filed 2019-11-12 | $109.19M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $33.04M 10-Q · filed 2019-08-08 | $59.16M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $26.13M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $6.65M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |